Targeted Hypoglossal Neurostimulation Study #2

NCT ID: NCT01796925

Last Updated: 2019-08-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

57 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-02-28

Study Completion Date

2014-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of the study is to confirm the safety and efficacy in patients utilizing the aura6000 System for the treatment of Obstructive Sleep Apnea (OSA).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sleep Apnea Syndromes Sleep Apnea, Obstructive Respiration Disorders Signs and Symptoms, Respiratory Syndrome, Obstructive Sleep Apnea

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

aura6000 THN Therapy

The aura6000 THN system will be implanted and activated for nightly therapy during sleep.

Group Type EXPERIMENTAL

aura6000 THN System

Intervention Type DEVICE

The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aura6000 THN System

The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* AHI \>20
* Noncompliant to CPAP
* Willing to provide informed consent
* Willing to comply with all follow-up visits and evaluations

Exclusion Criteria

* BMI limits
* COPD
* Central Sleep Apnea
* Anatomic variations interfering with device placement or stability.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

ImThera Medical, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Daniel Rodenstein, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Clinique Univ. Saint-Luc

Ofer Jacobowitz, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Hudson Valley ENT

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sharp Rees Stealy Medical Center

San Diego, California, United States

Site Status

Porter Adventist Hospital

Denver, Colorado, United States

Site Status

Chicago ENT

Chicago, Illinois, United States

Site Status

Orange Regional Medical Center

Middletown, New York, United States

Site Status

Clinique Univ. Saint-Luc

Brussels, , Belgium

Site Status

Pitié-Salpêtrière Hospital

Paris, , France

Site Status

Advanced Sleep Research

Berlin, , Germany

Site Status

St. Joseph-Stift

Bremen, , Germany

Site Status

G.B. Morgagni- L. Pierantoni Hospital

Forlì, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Belgium France Germany Italy

References

Explore related publications, articles, or registry entries linked to this study.

Zaidi FN, Meadows P, Jacobowitz O, Davidson TM. Tongue anatomy and physiology, the scientific basis for a novel targeted neurostimulation system designed for the treatment of obstructive sleep apnea. Neuromodulation. 2013 Jul-Aug;16(4):376-86; discussion 386. doi: 10.1111/j.1525-1403.2012.00514.x. Epub 2012 Aug 31.

Reference Type BACKGROUND
PMID: 22938390 (View on PubMed)

Mwenge GB, Rombaux P, Dury M, Lengele B, Rodenstein D. Targeted hypoglossal neurostimulation for obstructive sleep apnoea: a 1-year pilot study. Eur Respir J. 2013 Feb;41(2):360-7. doi: 10.1183/09031936.00042412. Epub 2012 May 17.

Reference Type BACKGROUND
PMID: 22599356 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IMT2012-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

StimAire Sleep Study
NCT05374941 TERMINATED NA
Chronic Evaluation of Respicardia Therapy
NCT01124370 COMPLETED PHASE2
remedē System Therapy Study
NCT03884660 ACTIVE_NOT_RECRUITING